<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>POLYETHYLENE GLYCOL 3350 NF PEGYLAX- polyethylene glycol 3350 powder, for solution </strong><br>MARTIN EKWEALOR PHARMACEUTICALS, INC.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-1"></a><p></p>
<h1>Directions</h1>
<p class="First">1. Note: This product cap is for dosing. A capful contains about 17 grams of powder.<br><br>2. Daily dose is 17 grams per day or as directed by physician.<br><br>3. pour 17 grams (about 1 heaping tablespoon) of powder into a cup.<br><br>4. Stir the powder in 4 to 8 oz. of water, juice, soda, coffee or tea until completely dissolved.<br><br>5. Drink the solution.<br><br>6. Treatment for 2 to 4 days may required to produce a bowel movement.<br><br>Keep this and all medications out of the reach of children.<br><br>Store at 20° - 25° C (68° - 77° F); excursions permitted to 15° - 30°(59° - 86° F). (See USP Controlled Room Temperature)<br><br>Lot # and Exp. Date:<br><br>Open here for more product information</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-2"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First">Polyethylene Glycol 3350 NF (Polyethylene Glycol 3350 Powder for Oral Solution) is a MEDICAL FOOD prescription only laxative which has been prescribed by your healthcare provider to manage <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. This product should only be used by the person for whom it was prescribed.<br><br><span class="Bold">How to take</span><br><br>The dose is 17 grams taken by mouth each day or as directed by your healthcare provider. Measure the dose using the product cap (or use one heaping tablespoon of powder), stir and dissolve in a glass (4 to 8 oz.) of water, juice, soda, coffee, or tea. Taking more than the prescribed dose may cause loss of fluid due to severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.<br><br><span class="Bold">How it will work</span><br><br>Polyethylene Glycol 3350 NF(PEG 3350)NF) softens the stool and increases the frequency of bowel movements by retaining water in the stool. Your first bowel movement will usually happen in two to four days, although results may vary for individual patients.<br><br><span class="Bold">How long should it take</span><br><br>Polyethylene Glycol 3350 NF achieves the best results when used between one and two weeks. You may discontinue therapy after you have had several satisfactory bowel movements or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Should unusual <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occur, consult your physician. Polyethylene Glycol 3350 NF is intended for up to a two week course of therapy. You should not use for a longer time unless directed by your physician.<br><br><span class="Bold">Next Steps</span><br><br>After successfully completing Polyethylene Glycol 3350 NF therapy (usually between one and two weeks,) please discuss with your healthcare provider lifestyle changes which may produce more regular bowel habits such as adequate dietary and fluid intake, and regular exercise.<br><br><span class="Bold">Who should not take Polyethylene Glycol 3350 NF</span><br><br>PEG 3350 NF should not be used by children and pregnant women unless prescribed by a physician.<br><br><span class="Bold">Side Effects/Drug Reactions</span><br><br>Occasionally, Polyethylene Glycol 3350 NF may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, stomach fullness, cramping, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and /or gas. Do not take if you have symptoms such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or distension, which may be due to <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>. On a rare occasions <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> have been reported which are suggestive of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. If you get an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> reaction, you should stop using PEG 3350 NF, and call your physician. if you are allergic to polyethylene glycol, do not use this product.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>Polyethylene Glycol 3350 NF
Polyethylene Glycol 3350 Powder for Oral Solution</h1>
<p class="First">A white powder for reconstitution. Polyethylene Glycol 3350 (Polyethylene Glycol 3350 Powder For Oral Solution) is a synthetic polyglycol having an average molecular weight of 3350. The actual molecular weight is not less than 90.0 percent and not greater than 110.0 percent of the normal  value. The chemical formula is HO(C2H4O)nH in which n represents the average number of ethylene groups. Below 55°  it is a free flowing white powder freely soluble in water. Polyethylene Glycol 3350 NF is an osmotic agent for the treatment of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Pharmacology: Polyethylene Glycol 3350 NF is an osmotic agent which causes water to be retained with the stool. Essentially, complete recovery of Polyethylene Glycol 3350 NF was shown in normal subjects without <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Attempts at recovery of Polyethylene Glycol 3350 NF in constipated patients resulted in incomplete and highly variable recovery. In vitro study showed indirectly that Polyethylene Glycol 3350 NF was not fermented into hydrogen or methane by the colonic mircoflora in human feces. Polyethylene Glycol 3355 NF appears to have no effect on the active absorption or secretion of glucose or electrolytes. There is no evidence of <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span>.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-5"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<p class="First">In one study, patients with less than 3 bowel movements per week were randomized to Polyethylene Glycol 3350 NF, 17 grams or placebo for 14 days. An increase in bowel movement frequency was observed for both treatment groups during the first week of treatment. Polyethylene Glycol 3350 NF was statistically superior to placebo during the second week of treatment. In another study, patients with 3 bowel movements or less per week and/or less than 300 grams of stool per week were randomized to 2 dose levels of Polyethylene Glycol 3350 NF or placebo for 10 days each. Success was defined by an increase in both bowel movement frequency and daily stool weight. For both parameters, superiority of the 17 gram dose of Polyethylene Glycol 3350 NF over the placebo was demonstrated.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-6"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For the treatment of occasional <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. This product should be used for 2 weeks or less as directed by a physician.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Polyethylene Glycol 3350 NF is contraindicated in patients with known or suspected <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> and patients known to be allergic to polyethylene glycol.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Patients with symptoms suggestive of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>) should be evaluated to rule out this condition before initiating Polyethylene Glycol 3350 NF therapy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold">General:</span> Patients presenting with complaints of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> should have a thorough medical history and physical examination to detect associated metabolic endocrine and neurogenic conditions and medications. A diagnostic evaluation should include a structural examination of the colon. Patients should be educated about a good defecatory and eating habits (such as high fiber diets) and lifestyle changes (adequate dietary fiber and fluid intake, regular exercise) which may produce regular bowel habits.<br><br>Polyethylene Glycol 3350 NF should be administered after being dissolved in approximately 4 to 8 ounces of water, juice, soda, coffee,or tea.<br><span class="Bold"><br>Information for Patients:</span> Polyethylene Glycol 3350 NF softens stool and increases the frequency of bowel movement by retaining water in the stool. It should always be taken by mouth after being dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea. Should unusual <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occur, consult your physician.<br><br>Two to four days may be required to produce a bowel movement. This product should be used for 2 weeks or less or as directed  by your physician. prolonged, frequent or excessive use of Polyethylene Glyycol 3350 NF may result in <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> and dependency on laxatives.<br><br><span class="Bold">Laboratory Tests:</span> No clinically significant effects on laboratory tests have been demonstrated.<br><br>Drug Interaction: No specific drug interactions have been demonstrated.<br><br><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>: Long term  carcinogenicity studies, genetic toxicity studies or reproductive toxicity studies in animals have not been performed with  Polyethylene Glycol 3350 NF.<br><br><span class="Bold">Pregnancy: Category C.</span> Animal reproductive studies have not been performed with Polyethylene Glycol 3350 NF. It is not known wheter Polyethylene Glycol 3350 NF can cause fetal harm when administered in a pregnant woman, or can affect reproductive capacity. Polyethylene Glycol 3350 NF should only be administered to a pregnant woman if clearly needed.<br><br><span class="Bold">Pediatric Use:</span> Safety and effectiveness in pediatric patients has not been established.<br><br><span class="Bold">Geriatric Use:</span> There is no evidence for special consideration when Polyethylene Glycol 3350 NF is administered to elderly patients. In geriatric nursing home patients a higher incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred at the recommended 17 g dose. If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs Polyethylene Glycol 3350 NF should be discontinued..</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">abdominal bloating</span>, cramping and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> may occur. High doses may produce <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and excessive stool frequency, particularly in elderly nursing home patients. Patients taking other medications containing polyethylene glycol occasionally developed <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> suggestive of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">OVERDOSE</span></h1>
<p class="First">There have been no reports of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> would be the expected major event. If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurred without conomitant ingestion of fluids, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> due to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may result. Treatment should be terminated and free water administered. The oral LD50 is &gt;50g/kg in mice, rats and rabbits.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual dose is 17 grams (about 1 heaping tablespoon) of powder in 4 to 8 ounces of water, juice, soda, coffee or tea daily or as directed by physician. Each bottle of Polyethylene Glycol 3350 NF has a cap that holds 17 grams of laxative powder when filled to the top.Two to four days (48 to 96 hours0 may be required to produce a bowel movement.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PEG 3350 NF is supplied in powder form for oral administration after dissolution in water, juice, soda, coffee, or tea.<br><br>Rx only.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="section-14"></a><p></p>
<h1>Keep this and all medication out of the reach of children.</h1>
<p class="First"><span class="Bold">Keep this and all medication out of the reach of children.</span></p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Store at 20°-25°C (68°-77°F): excursions permitted to 15°-30°C (59°-86°F).<br><br>(See USP Controlled Room Temperature)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>Product Label
Product Insert</h1>
<p class="First"><span class="Bold">M.E. Pharmaceuticals, Inc.</span></p>
<p><span class="Bold">58607-700-57</span><br><span class="Bold"><br>Prescription Powder for Oral Solution</span><br><br><span class="Bold">Polyethylene </span><br><br><span class="Bold">Gylcol 3350 NF</span><br><br><span class="Bold">PEGyLAX</span><br><br><span class="Bold">Rx Only</span><br><br><span class="Bold">527 Grams</span><br><br><span class="Bold">MADE WITH PRIDE IN THE U.S.A.</span><br><br>M.E. Pharmaceuticals, Inc.<br><br>Richmond, IN 47374</p>
<br><p><img alt="ME PolyGlycol Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bcd57d3c-e1c4-474f-a757-ca89b020278b&amp;name=MEPharma_PolyGlycol.jpg"></p>
<br><p><img alt="ME PolyGlycol1 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bcd57d3c-e1c4-474f-a757-ca89b020278b&amp;name=MEPharma_PolyGlycol1.jpg"></p>
<br><p><img alt="ME PolyGlycol2 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bcd57d3c-e1c4-474f-a757-ca89b020278b&amp;name=MEPharma_PolyGlycol2.jpg"></p>
<br><p><img alt="ME PolyGlycol3 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bcd57d3c-e1c4-474f-a757-ca89b020278b&amp;name=MEPharma_PolyGlycol3.jpg"></p>
<p><img alt="ME PolyGlycol4 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bcd57d3c-e1c4-474f-a757-ca89b020278b&amp;name=MEPharma_PolyGlycol4.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POLYETHYLENE GLYCOL 3350 NF 		
					PEGYLAX</strong><br><span class="contentTableReg">polyethylene glycol 3350 powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58607-700</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POLYETHYLENE GLYCOL 3350</strong> (POLYETHYLENE GLYCOL 3350) </td>
<td class="formItem">POLYETHYLENE GLYCOL 3350</td>
<td class="formItem">17 g  in 17 g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58607-700-57</td>
<td class="formItem">527 g in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">12/16/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>MARTIN EKWEALOR PHARMACEUTICALS, INC.
							(624528386)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>MARTIN EKWEALOR PHARMACEUTICALS, INC. (624528386)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">MARTIN EKWEALOR PHARMACEUTICALS, INC.</td>
<td class="formItem"></td>
<td class="formItem">624528386</td>
<td class="formItem">manufacture(58607-700)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7622102b-138b-4991-91dd-72eeeb58f2b8</div>
<div>Set id: bcd57d3c-e1c4-474f-a757-ca89b020278b</div>
<div>Version: 1</div>
<div>Effective Time: 20131213</div>
</div>
</div> <div class="DistributorName">MARTIN EKWEALOR PHARMACEUTICALS, INC.</div></p>
</body></html>
